期刊文献+

非瓣膜性心房颤动与脑梗死的相关因素分析 被引量:4

Analysis of the related factors between the nonvalvular atrial fibrillation and the cerebral infarction
下载PDF
导出
摘要 目的:探讨非瓣膜性心房颤动患者血小板平均体积(MPV)、纤维蛋白原(FI)、左房内径(LAD)与缺血性脑梗死之间的关系。方法:选取165位平均年龄(75.8±7.6)岁的慢性心房颤动患者,根据CT和/或MRI检查确诊为脑梗死,分为心房颤动合并脑梗死(n=80)和单纯心房颤动(n=85),分别评估两组患者CHA2DS2-vasc积分、MPV、FI、LAD、血压、血脂和肾功能之间的差异。结果:心房颤动合并脑梗死和单纯心房颤动患者在CHA2DS2-vasc积分(P<0.001)、MPV(P<0.001)、FI(P=0.002)、血清脂蛋白(a)(P=0.017)、LAD(P<0.001)、空腹血浆葡萄糖(P=0.034)之间存在明显的统计学差异,logistic回归分析显示CHA2DS2-vas、MPV、FI、LAD是心房颤动相关脑梗死的独立危险因素。结论:除CHA2DS2-vasc评分系统外,联合测定MPV、FI和LAD预测非瓣膜性心房颤动发生脑梗死具有重要的临床价值。 Objective: To explore the relationship among the mean platelet volume, fibrinogen and left atrialsize and cerebral infarction in patients with nonvalvular atrial fibrillation (AF). Methods: One hundred and sixty- five patients with AF were divided into AF with and without cerebral infarction diagnosed with computed tomography (CT) and/or magnetic resonance imaging (MRI). CHA2DS2-vasc score, mean platelet volume, plasma fibrinogen, left atrial size, blood pressure, serum lipid level and renal function were detected in the enrolled population. Results: Compared with the patients without cerebral infarction, the AF patients with cerebral infarction showed higher level of CHA2DS2-vasc score (P〈0.001), plasma fibrinogen (P=0.002), mean plate- let volume (P〈0.001), fasting plasma glucose (P=0.034), lipoprotein (a) (P=0.017) and larger left atrial size (P 〈0.001). After adjustment of multiple traditional cardiovascular risk factors, logistic regression analysis showed that mean platelet volume, plasma fibrinogen, left atrial size and CHA2DS2-vasc score were independent risk factors for AF-related cerebral infarction. Conclusion: Except CHA2DS2-vasc score, the combined index of mean platelet volume, plasma fibrinogen and left atrial size may also play an important role in predicting the occurrence of cerebral infarction in patients with AF.
出处 《温州医学院学报》 CAS 2014年第1期44-47,共4页 Journal of Wenzhou Medical College
关键词 心房颤动 脑梗死 血小板平均体积 纤维蛋白原 左房内径 atrial fibrillation cerebral infarction mean platelet volume fibrinogen left atrial size
  • 相关文献

参考文献15

  • 1Camm AJ,Lip GY,De Caterina R. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation:an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association[J].EUROPACE,2012,(10):1385-1413. 被引量:1
  • 2Bouzas-Mosquera A,Broull6n FJ,Alvarez-García N. Left atrial size and risk for all-cause mortality and ischemic stroke[J].Canadian Medical Association Journal,2011,(10):E657-E664. 被引量:1
  • 3Pisters R,Lane DA,Marin F. Stroke and thromboembolism in atrial fibrillation[J].Circulation,2012,(10):2289-2304. 被引量:1
  • 4Bath P,Algert C,Chapman N. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease[J].STROKE,2004,(03):622-626. 被引量:1
  • 5Lang RM,Bierig M,Devereux RB. Recommendations for chamber quantification:a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group,developed in conjunction with the European Association of Echocardiography,a branch of the European Society of Cardiology[J].Journal of the American Society of Echocardiography,2005,(12):1440-1463. 被引量:1
  • 6Magnani JW,Rienstra M,Lin H. Atrial fibrillation:Current knowledge and future directions in epidemiology and genomics[J].CIRCULATION,2011,(18):1982-1993. 被引量:1
  • 7Abhayaratna WP,Seward JB,Appleton CP. Left atrial size:physiologic determinants and clinical applications[J].Journal of the American College of Cardiology,2006,(12):2357-2363. 被引量:1
  • 8Van der Loo B,Martin JF. A role for changes in platelet production in the cause of acute coronary syndromes[J].Arteriosclerosis Thrombosis and Vascular Biology,1999,(03):672-679. 被引量:1
  • 9Khode V,Sindhur J,Kanbur D. Mean platelet volume and other platelet volume indices in patients with stable coronary artery disease and acute myocardial infarction:A case control study[J].Journal of Cardiovascular Disease Research,2012,(04):272-275. 被引量:1
  • 10Turfan M,Erdogan E,Ertas G. Usefulness of mean platelet volume for predicting stroke risk in atrial fibrillation patients[J].Blood Coagulation & Fibrinolysis,2013,(01):55-58. 被引量:1

二级参考文献11

  • 1Davalos A. Mechanisms of worsening in progressing stroke: from the laboratory to the clinical setting[J] .Methods Find Exp Clin Pharmacol,1997,19 (Suppl A):65- 67. 被引量:1
  • 2Jorgensen HS, Nakayama H, Raaschou HO, et al. Effect of blood pressure and diabetes on stroke in progression[J]. Lancet, 1994,344(8916): 156 - 159. 被引量:1
  • 3Toni D, Fiorelli M, Gentile M, et al. Progressing neurological deficit secodary to acute ischemic stroke: a study on predictability, pathogenesis, and prognosis[J]. Arch Neurol, 1995,52(7) :670 - 675. 被引量:1
  • 4Davalos A, Castillo J, Serena J, et al. Duration of glutamate release after acute ischemic stroke[J] .Stroke, 1997,28(4) :708 - 710. 被引量:1
  • 5Castillo J. Deteriorating stroke: diagnostic criteria, predictors, mechanisms and treatment[J]. Cerebrovasc Dis, 1999,9(Suppl 3):1- 8. 被引量:1
  • 6Castillo L Noya M. Mechanisms of progressing of cerebral infarction[J]. Neurologia, 1999,14(Suppl 2):2 - 12. 被引量:1
  • 7Clark WM. Cytokines and reperfusion injury[J]. Neurology,1997,49(Suppl 4) :S10 - 14. 被引量:1
  • 8Vila N, Castillo J, Davalos A, et al. Levels of anti-inflammatory cytakines and neurological worsening in acute ischemic stroke[J]. Stroke,2003,34(3) :671 - 675. 被引量:1
  • 9Tarkowski E, Rosengren L, Blomstrand C, et al. Intrathecal release of pro- and anti-inflammatory cytokines during stroke[J]. Clin Exp Immunol, 1997,110(3) :492 - 499. 被引量:1
  • 10Vila N, Castilo J, Davalos A, et al. Proinflammatory cytokines and ealy neurological worsening in ischemic artoke[J]. Stroke, 2000,31(10) :2325 - 2329. 被引量:1

共引文献3

同被引文献59

  • 1周巍,马晓峰.心房颤动合并脑卒中患者外周血RBP、IL-6表达及临床意义[J].湖南师范大学学报(医学版),2021,18(6):21-24. 被引量:4
  • 2各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量:33008
  • 3Shah AJ,Liu X.,Hadidi AS,et al.Early management of atrial fibrillation:from imaging to drugs to ablation[J].Nat Rev Cardiol,2010,7(6):345-354. 被引量:1
  • 4Magnani JW,Rienstra M,Lin H,et al.Atrial fibrillation:current knowledge and future directions in epidemiology and genomics[J].Circulation,2011,124(18):1982-1993. 被引量:1
  • 5Gattellari M,Goumas C,Aitken R,et al.Outcomes for patients with ischaemic stroke and atrial fibrillation:the PRISM study[J].Cerebrovasc Dis,2011,32(4):370-382. 被引量:1
  • 6Camm AJ,Lip GY,De Caterina R,et al,2012 focused update of the ESC Guidelines for the management of atrial fibrillation:an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association[J].Europace,2012,14(10):1385-1413. 被引量:1
  • 7Turpie AG.Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation[J].Ther Clin Risk Manag,2014,10:197-205. 被引量:1
  • 8Colilla S,Crow A,Simon T,et al.Projected estimates of prevalence and annual growth rate of atrial fibrillation in the United States from a dynamic age-period progression model[J].Circ Cardiovasc Qual 0utcomes,2012,5:A2056. 被引量:1
  • 9Fuster V,Ryden LE,Cannom DS,et al.ACC/AHA/ESC 2006 guide-lines for the management of patients with atrial fibrillation:full text:a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee fox practice guide-lines(writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation)developed in collaboration with the European heart rhythm association and the heart rhythm society[J].Europace,2006,8(9):651-745. 被引量:1
  • 10Pieri A,Lopes TO,Gabhai AA,Stratification with CHA2DS2-VASc score is better than CHADS2 score in reducing ischemic stroke risk in patients with atrial fibrillation[J].Int J Stroke,2011,6(5):466. 被引量:1

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部